STOCK TITAN

REGENXBIO (RGNX) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

REGENXBIO Inc. director David C. Stump reported equity compensation awards, not open-market purchases. He received 9,807 shares of common stock underlying a time-based restricted stock unit that will vest on May 29, 2027, subject to his continuous service to the company.

He was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which vest on May 29, 2027 and expire on May 29, 2036. Following these awards, he holds 28,861 shares of common stock directly.

Positive

  • None.

Negative

  • None.
Insider STUMP DAVID C
Role null
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 46,600 $0.00 --
Grant/Award Common Stock 9,807 $0.00 --
Holdings After Transaction: Stock Options (Right to Buy) — 46,600 shares (Direct, null); Common Stock — 28,861 shares (Direct, null)
Footnotes (1)
  1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
RSU shares granted 9,807 shares Common stock underlying time-based RSU award granted May 29, 2026
RSU vesting date May 29, 2027 100% of RSU shares vest on this date, subject to service
Options granted 46,600 shares Stock options (right to buy) granted May 29, 2026
Option exercise price $7.01 per share Conversion or exercise price for the stock options
Option vesting date May 29, 2027 Options vest on this date, subject to continuous service
Option expiration May 29, 2036 Expiration date if options are not exercised earlier
Shares owned after awards 28,861 shares Total direct common stock holdings following reported transactions
restricted stock unit financial
"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with 46,600.0000 shares and a $7.0100 exercise price."
exercise price financial
"conversion_or_exercise_price: "7.0100" for the stock options grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous service financial
"will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer."
expiration date financial
"expiration_date: "2036-05-29T00:00:00.000Z" for the stock options."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
STUMP DAVID C

(Last)(First)(Middle)
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/29/2026A9,807(1)A$0.0028,861D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$7.0105/29/2026A46,60005/29/2027(2)05/29/2036Common Stock46,600$0.0046,600D
Explanation of Responses:
1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Remarks:
/s/ Patrick J. Christmas as attorney-in-fact06/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did REGENXBIO (RGNX) director David C. Stump receive?

David C. Stump received 9,807 shares of common stock underlying a restricted stock unit and stock options for 46,600 shares at a $7.01 exercise price. Both awards were granted as equity compensation rather than open-market purchases.

When do David C. Stump’s new REGENXBIO (RGNX) RSUs vest?

The 9,807 restricted stock unit shares will vest on May 29, 2027, provided Stump maintains continuous service with REGENXBIO. Vesting means the shares become fully earned and transferable, turning the RSU award into actual common stock ownership at that date.

What are the key terms of David C. Stump’s REGENXBIO (RGNX) stock options?

Stump’s stock options cover 46,600 shares of common stock with a $7.01 exercise price. The options vest on May 29, 2027, contingent on continuous service, and expire on May 29, 2036 if not exercised before that expiration date.

How many REGENXBIO (RGNX) shares does David C. Stump hold after these awards?

After the reported equity awards, Stump directly owns 28,861 shares of REGENXBIO common stock. This figure reflects his updated direct holdings following the grant of the new restricted stock unit and stock option awards reported in the filing.

Were David C. Stump’s REGENXBIO (RGNX) awards open-market stock purchases?

No. The filing describes the transactions as equity grants, including restricted stock units and stock options, with a transaction price per share of $0.00. These represent compensation awards from the company rather than shares bought on the open market.

What conditions apply to David C. Stump’s new REGENXBIO (RGNX) equity awards?

Both the RSU award and the stock options vest on May 29, 2027, subject to Stump’s continuous service to REGENXBIO. If continuous service conditions are not met, the awards may not fully vest according to the terms described in the filing.